In the field of i.e. Diabetes therapy, the Insulin biosimilar interchangeability and switching discussion is by lack of data from clinical trials still a matter of Assumption Based Medicine as opposed to Evidence Based Medicine.
Cost - benefit comparisons only provide relevant results when they compare…hammers to hammers:-)